在难治性强迫症治疗中，将地昔帕明添加到5-羟色胺再摄取抑制剂中。
Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
作者信息
Barr L C, Goodman W K, Anand A, McDougle C J, Price L H
机构信息
Clinical Neuroscience Research Unit, Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, USA.
出版信息
Am J Psychiatry. 1997 Sep;154(9):1293-5. doi: 10.1176/ajp.154.9.1293.
OBJECTIVE
The purpose of this study was to determine whether combined treatment with a selective serotonin reuptake inhibitor (SSRI) and a norepinephrine reuptake inhibitor, desipramine, effectively reduces obsessive-compulsive symptoms in patients who do not respond to SSRIs.
METHOD
In a double-blind study, desipramine or placebo was added for 6 or 10 weeks to the treatment of 30 patients with obsessive-compulsive disorder whose symptoms were refractory to SSRI treatment (fluvoxamine, fluoxetine, or sertraline) alone.
RESULTS
There were no significant differences between the adjunctive desipramine and placebo groups in obsessive-compulsive or depressive symptoms.
CONCLUSIONS
These data suggest that clomipramine's possibly superior efficacy in the treatment of obsessive-compulsive symptoms may not stem from its capacity to inhibit reuptake of norepinephrine.
目的
本研究旨在确定选择性5-羟色胺再摄取抑制剂（SSRI）与去甲丙咪嗪（一种去甲肾上腺素再摄取抑制剂）联合治疗对SSRI治疗无效的强迫症患者是否能有效减轻强迫症状。
方法
在一项双盲研究中，30名强迫症症状单独使用SSRI（氟伏沙明、氟西汀或舍曲林）治疗无效的患者，被添加去甲丙咪嗪或安慰剂治疗6周或10周。
结果
在强迫症状或抑郁症状方面，添加去甲丙咪嗪组与安慰剂组之间无显著差异。
结论
这些数据表明，氯米帕明治疗强迫症状时可能具有的优越疗效，可能并非源于其抑制去甲肾上腺素再摄取的能力。
Zotero 插件